WO2009005046A1 - Agent thérapeutique pour colite ulcérative, comprenant de la mizoribine - Google Patents

Agent thérapeutique pour colite ulcérative, comprenant de la mizoribine Download PDF

Info

Publication number
WO2009005046A1
WO2009005046A1 PCT/JP2008/061877 JP2008061877W WO2009005046A1 WO 2009005046 A1 WO2009005046 A1 WO 2009005046A1 JP 2008061877 W JP2008061877 W JP 2008061877W WO 2009005046 A1 WO2009005046 A1 WO 2009005046A1
Authority
WO
WIPO (PCT)
Prior art keywords
ulcerative colitis
therapeutic agent
mizoribine
patient
leukocytapheresis
Prior art date
Application number
PCT/JP2008/061877
Other languages
English (en)
Japanese (ja)
Inventor
Tetsuya Ishida
Original Assignee
Asahi Kasei Kuraray Medical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asahi Kasei Kuraray Medical Co., Ltd. filed Critical Asahi Kasei Kuraray Medical Co., Ltd.
Priority to CN2008800208680A priority Critical patent/CN101687899B/zh
Priority to KR1020097025758A priority patent/KR101239541B1/ko
Priority to JP2009521631A priority patent/JP5697070B2/ja
Publication of WO2009005046A1 publication Critical patent/WO2009005046A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention porte sur un agent thérapeutique pour colite ulcérative, qui comprend de la mizoribine, présente un effet thérapeutique sur la colite ulcérative, ne pose pas de problèmes concernant l'apparition d'un effet secondaire défavorable pendant le maintien de la rémission de la colite ulcérative, et peut être administré pendant une longue période de temps. De façon spécifique, l'invention porte sur un agent thérapeutique pour la colite ulcérative, qui comprend de la mizoribine. L'agent thérapeutique peut être utilisé pour un patient atteint de colite ulcérative qui a reçu une thérapie par leucocytaphérèse et auquel on n'a pas administré un quelconque agent d'immunosuppression autre que la mizoribine au moins après que la thérapie par leucocytaphérèse a commencé. L'administration d'agent thérapeutique au patient est commencée à un moment de temps qui se situe pendant l'application de la thérapie par leucocytaphérèse et après que la condition clinique du patient est améliorée. L'agent thérapeutique est administré au patient au moins une fois par jour de telle sorte que le taux maximal de mizoribine dans le sang dans le patient devienne non inférieur à 0,6 µg/ml et inférieur à 1,5 µg/ml.
PCT/JP2008/061877 2007-07-02 2008-07-01 Agent thérapeutique pour colite ulcérative, comprenant de la mizoribine WO2009005046A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN2008800208680A CN101687899B (zh) 2007-07-02 2008-07-01 含有咪唑立宾的溃疡性结肠炎治疗药
KR1020097025758A KR101239541B1 (ko) 2007-07-02 2008-07-01 미조리빈을 함유하는 궤양성 대장염 치료약
JP2009521631A JP5697070B2 (ja) 2007-07-02 2008-07-01 ミゾリビンを含有する潰瘍性大腸炎治療薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007173707 2007-07-02
JP2007-173707 2007-07-02

Publications (1)

Publication Number Publication Date
WO2009005046A1 true WO2009005046A1 (fr) 2009-01-08

Family

ID=40226090

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061877 WO2009005046A1 (fr) 2007-07-02 2008-07-01 Agent thérapeutique pour colite ulcérative, comprenant de la mizoribine

Country Status (4)

Country Link
JP (1) JP5697070B2 (fr)
KR (1) KR101239541B1 (fr)
CN (1) CN101687899B (fr)
WO (1) WO2009005046A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9782707B2 (en) 2014-03-24 2017-10-10 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US9796166B2 (en) 2014-03-24 2017-10-24 Fenwal, Inc. Flexible biological fluid filters
US9968738B2 (en) 2014-03-24 2018-05-15 Fenwal, Inc. Biological fluid filters with molded frame and methods for making such filters
US10159778B2 (en) 2014-03-24 2018-12-25 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US10376627B2 (en) 2014-03-24 2019-08-13 Fenwal, Inc. Flexible biological fluid filters

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037837A1 (fr) * 2003-10-17 2005-04-28 Nippon Kayaku Kabushiki Kaisha Derive 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine substitue et utilisation de ce derive
WO2005123061A1 (fr) * 2004-06-18 2005-12-29 Tillotts Pharma Ag Compositions pharmaceutiques renfermant un acide gras poly-insature et au moins un agent immunosuppresseur ou un agent ainti-neoplasique
WO2006129786A1 (fr) * 2005-06-02 2006-12-07 Akira Matsumori Procedes permettant de diagnostiquer, de prevenir et de traiter une infection induite par le virus de l’hepatite c
JP2007050013A (ja) * 2005-08-15 2007-03-01 Asahi Kasei Medical Co Ltd 白血球除去方法および白血球除去フィルター
JP2007055900A (ja) * 2003-12-15 2007-03-08 Ajinomoto Co Inc 炎症性疾患の治療及び予防用医薬組成物
JP2007159874A (ja) * 2005-12-15 2007-06-28 Asahi Kasei Corp リガンド固定化用基材および細胞選択吸着材

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037837A1 (fr) * 2003-10-17 2005-04-28 Nippon Kayaku Kabushiki Kaisha Derive 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine substitue et utilisation de ce derive
JP2007055900A (ja) * 2003-12-15 2007-03-08 Ajinomoto Co Inc 炎症性疾患の治療及び予防用医薬組成物
WO2005123061A1 (fr) * 2004-06-18 2005-12-29 Tillotts Pharma Ag Compositions pharmaceutiques renfermant un acide gras poly-insature et au moins un agent immunosuppresseur ou un agent ainti-neoplasique
WO2006129786A1 (fr) * 2005-06-02 2006-12-07 Akira Matsumori Procedes permettant de diagnostiquer, de prevenir et de traiter une infection induite par le virus de l’hepatite c
JP2007050013A (ja) * 2005-08-15 2007-03-01 Asahi Kasei Medical Co Ltd 白血球除去方法および白血球除去フィルター
JP2007159874A (ja) * 2005-12-15 2007-06-28 Asahi Kasei Corp リガンド固定化用基材および細胞選択吸着材

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Nanchisei Enshosei Chokan Shogai ni Kansuru Chosa Kenkyu", KOSEI KAGAKU KENKYUHI HOJOKIN TOKUTEI SHIKKAN TAISAKU KENKYU JOGYO. HAN HEISEI 13 NENDO KENKYU HOKOKUSHO, March 2002 (2002-03-01), pages 49 - 50 *
KOSEISHO TOKUTEI SHIKKAN NANCHISEI ENSHOSEI CHOKAN SHOGAI CHOSA KENKYUHAN HEISEI 10 NENDO KENKYU HOKOKUSHO, March 1999 (1999-03-01), pages 130 - 131 *
NANCHISEI ENSHOSEI CHOKAN SHOGAI NI KANSURU CHOSA KEKYU, KOSEI RODO KAGAKU KENKYUHI HOJOKIN NANCHISEI SHIKKAN KOKUFUKU KENKYU JOGYO. HEISEI 17 NENDO KENKYU HOKOKUSHO, March 2006 (2006-03-01), pages 13 - 15 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9782707B2 (en) 2014-03-24 2017-10-10 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US9796166B2 (en) 2014-03-24 2017-10-24 Fenwal, Inc. Flexible biological fluid filters
US9968738B2 (en) 2014-03-24 2018-05-15 Fenwal, Inc. Biological fluid filters with molded frame and methods for making such filters
US10159778B2 (en) 2014-03-24 2018-12-25 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US10183475B2 (en) 2014-03-24 2019-01-22 Fenwal, Inc. Flexible biological fluid filters
US10343093B2 (en) 2014-03-24 2019-07-09 Fenwal, Inc. Biological fluid filters having flexible walls and methods for making such filters
US10376627B2 (en) 2014-03-24 2019-08-13 Fenwal, Inc. Flexible biological fluid filters

Also Published As

Publication number Publication date
CN101687899A (zh) 2010-03-31
KR20090130349A (ko) 2009-12-22
KR101239541B1 (ko) 2013-03-06
JPWO2009005046A1 (ja) 2010-08-26
CN101687899B (zh) 2012-11-28
JP5697070B2 (ja) 2015-04-08

Similar Documents

Publication Publication Date Title
CA2549801A1 (fr) Amelioration des fonctions renales par le treprostinil
CA2393437A1 (fr) Formulation a base d'exo-s-mecamylamine et utilisation en traitement
JP2010525050A5 (fr)
EP2216024A3 (fr) Utilisation de ranolazine pour le traitement de maladies cardiovasculaires
MX336657B (es) Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
WO2009002867A3 (fr) Forme posologique à unités multiples contenant un agent thérapeutique en combinaison avec un complément alimentaire
CA2574450A1 (fr) Methode pour traiter l'hyperphosphatemie au moyen d'hydroxycarbonate de lanthane
WO2007149283A3 (fr) Procédé servant à raccourcir le séjour hospitalier de patients atteints d'insuffisance cardiaque globale et de surchage liquide aiguë
NZ608292A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
WO2009005046A1 (fr) Agent thérapeutique pour colite ulcérative, comprenant de la mizoribine
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
MX2020001342A (es) Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas.
JP2004508280A5 (fr)
WO2008150565A3 (fr) Utilisation de ranolazine pour peptide cérébral natriurétique élevé
WO2012044783A3 (fr) Procédé d'obtention d'une concentration de thymosine bêta 4 dans un patient humain
WO2008051527A3 (fr) Libération prolongée d'agents pour la gestion d'une douleur localisée
WO2012058276A3 (fr) Procédés et matériaux permettant la réduction de facteurs de risques multiples associés au syndrome métabolique
WO2012082765A3 (fr) Méthodes pour réduire le poids corporel et traiter le diabète
WO2004096141A3 (fr) Procede destine a favoriser un sommeil ininterrompu par l'administration d'un chlorure de trospium
Obeso et al. Subcutaneous administration of lisuride in the treatment of complex motor fluctuations in Parkinson’s disease
Petkova et al. Oral application of sodium pyruvate in healthy persons and patients with diabetes mellitus type I
MX359768B (es) Métodos para controlar la presión arterial y para reducir la disnea durante una insuficiencia cardiaca.
WO2008079818A3 (fr) Administration intraveineuse de formulations analgésiques hydrosolubles
Morales Bradycardia and hypotension: case report
MY163107A (en) Pharmaceutical composition for the treatment of bladder disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880020868.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08777728

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20097025758

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009521631

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08777728

Country of ref document: EP

Kind code of ref document: A1